These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12124177)

  • 1. Critical role for Gab2 in transformation by BCR/ABL.
    Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
    Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
    Cortez D; Kadlec L; Pendergast AM
    Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Million RP; Van Etten RA
    Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
    Million RP; Harakawa N; Roumiantsev S; Varticovski L; Van Etten RA
    Mol Cell Biol; 2004 Jun; 24(11):4685-95. PubMed ID: 15143164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
    Gaston I; Johnson KJ; Oda T; Bhat A; Reis M; Langdon W; Shen L; Deininger MW; Druker BJ
    Exp Hematol; 2004 Jan; 32(1):113-21. PubMed ID: 14725908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.
    Dorsey JF; Cunnick JM; Mane SM; Wu J
    Blood; 2002 Feb; 99(4):1388-97. PubMed ID: 11830491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
    Samanta A; Perazzona B; Chakraborty S; Sun X; Modi H; Bhatia R; Priebe W; Arlinghaus R
    Leukemia; 2011 Mar; 25(3):463-72. PubMed ID: 21183952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
    Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
    EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
    EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
    Kim JH; Chu SC; Gramlich JL; Pride YB; Babendreier E; Chauhan D; Salgia R; Podar K; Griffin JD; Sattler M
    Blood; 2005 Feb; 105(4):1717-23. PubMed ID: 15486067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.